NL-OMON40301已完成不适用
A Double-blind, Placebo-Controlled, Randomized, 4-Week, Multiple-Dose, Proof-of-Mechanism Study in Subjects with Early Alzheimer*s Disease Investigating the Effects of JNJ-54861911 on Aß Processing in CSF and Plasma - Phase 1 B: JNJ-54861911 in Subjects with Early Alzheimer*s Disease
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Each potential subject must satisfy all of the following criteria to be enrolled in the study unless otherwise specified:;1. Criterion Modified per amendment;1.1 Subjects with prodromal AD: Subject must be a man or woman between 50 and 90 years of age, inclusive.;Subjects who are asymptomatic at risk for AD: Subject must be a man or woman between 60 and 85 years of age, inclusive.;2. Criterion modified per amendment;2.1 Subjects must have had sufficient education or work experience to exclude mental retardation and must be able to read and write.;3. Criterion Modified per amendment;3.1 Subjects with prodromal AD: Subjects must have a CDR score of 0.5 consistent with MCI.;Subjects who are asymptomatic at risk for AD: Subjects must have a CDR score of 0 and as such rated as normal.;4. Criterion modified per amendment;4.1 Subjects must have evidence of amyloid deposition by means of either:;a) low CSF Aß1-42 levels at screening;b) a positive amyloid positron emission tomography (PET) amyloid scan at screening (optional depending on the site*s PET capability);;5. Subjects must have a body mass index (BMI=weight/height²) between 18 and 35 kg/m2, inclusive, at screening.;6. Before randomization, a woman must be not of childbearing potential: premenarchal; postmenopausal (>=50 years of age with amenorrhea for at least 12 months; permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy); or otherwise be incapable of pregnancy,;7. A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug. In addition, their female partners should also use an appropriate method of birth control for at least the same duration.;8. Subjects must be otherwise healthy for their age group or medically stable with or without medication on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening or at baseline. If there are abnormalities, they must be consistent with the underlying illness in the study population.;9. Subjects must be otherwise healthy or medically stable on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel [including liver enzymes, other specific tests], hematology, or urinalysis are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the subject*s source documents and initialed by the investigator.;10. Subjects must have a reliable informant (relative, partner, friend, *);11. Subject must be able to be compliant with self-administration of medication;12. Subject must be able to swallow drug as a whole.;13. Subject must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.;14. Subject must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
排除标准
- •Any potential subject who meets any of the following criteria will be excluded from participating in the study unless otherwise specified:;1. Criterion modified per amendment;1.1 Subject has evidence of any brain disease, other than potential very early signs of AD (e.g. mild hippocampal atrophy) or typical age related changes (e.g. mild white matter hyperintensity on MRI) or any other abnormality (e.g. folic acid/Vitamin B12 deficiency) that could explain a possible cognitive deficit (including, but not limited to vascular encephalopathy or strokes, as imaged by cerebral MRI and Major Depression, as defined by DSM-IV criteria).;2. Subject has been diagnosed with dementia due to AD, due to other diseases, or with AD and contribution of other disorders (mixed dementia):;Degenerative dementia such as: frontal lobe dementia, cortical basal dementia, progressive supranuclear palsy and primary progressive aphasia; dementia associated with significant Parkinsonism, e.g. Parkinson*s Disease, diffuse Lewy body disease; multi infarct dementia (vascular dementia,); primary and secondary brain tumor; genetic disorder associated with dementia (Huntington*s disease, Pick*s disease, fronto-temporal dementia, hereditary ataxias, early-onset familial AD); dementia due to sporadic or familiar forms of prion diseases , e.g. Creutzfeldt-Jakob disease; diffuse white matter disease; normal-pressure hydrocephalus; head injury leading to cognitive decline; recently diagnosed or untreated thyroid disease; vitamin B12 or folic acid deficiency; drug and medication intoxication; severe depression (pseudo dementia); chromosome 21 trisomy (Down Syndrome); neurosyphilis; HIV dementia;;3. Subject has evidence of familial autosomal dominant Alzheimer*s Disease;4. Subject has any contra-indications for MRI (prostheses, implants, claustrophobia, pacemakers, etc.);5. Subject has a clinically significant abnormal physical- or neurological examination, vital signs or 12-lead ECG (incl. QTc>450msec for males and females, Left Bundle Branch Block, AV Block second degree or higher, permanent pacemaker or implantable cardioverter defibrillator (ICD)) at screening or baseline (Day 1 predose), which in the opinion of the investigator is not appropriate and reasonable for the population under study.;6. Criteria modified per amendment;6.1. Subject has a relevant history of or current neurological disease other than asymptomatic at risk for AD/pAD/MCI (including any history of post-lumbar puncture headache), which in the opinion of the investigator may make interpretation of possible new neurological signs or symptoms difficult.;7. Criteria modified per amendment;7.1.Subject has a history of or current liver or renal insufficiency; clinically significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, hematologic, rheumatologic, psychiatric, or metabolic disturbances (e.g. instable situation needing monitoring or regular dose adaptations).;8. Subject has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence).;9. Subject has a history of spontaneous, prolonged or severe bleeding of unclear origin.;10. Criterion modified per amendment.;10.1. Subject has a history of epilepsy or fits or unexplained black-outs o
研究者
相似试验
进行中（未招募）
1 期
RCT of Medical Cannabis Aerosol for DPNP TreatmentDiabetic Peripheral Neuropathic PainMedDRA version: 21.1Level: LLTClassification code: 10067547Term: Diabetic peripheral neuropathic pain Class: 10029205CTIS2023-508932-68-00Syqe Medical Ltd.192
已完成
2 期
Soluble fibre for asthma controlAsthmaACTRN12618001362280niversity of Newcastle40
进行中（未招募）
不适用
A comparison study of LMTM and placebo in patients with Alzheimer’s Disease currently taking prespecified medicationsAlzheimer’s DiseaseMedDRA version: 14.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2011-005292-17-DETauRx Therapeutics Ltd60
进行中（未招募）
不适用
A comparison study of LMTM and placebo in patients with Alzheimer’s Disease currently taking pre-specified medicationsAlzheimer’s DiseaseMedDRA version: 14.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2011-005292-17-GBTauRx Therapeutics Ltd60
已完成
不适用
A randomized, double-blind, placebo-controlled, 4-period, two part cross-over study to evaluate the potential interaction effect between 4 mg/kg and 16 mg/kg sugammadex and enoxaparin or unfractionated heparin on anticoagulation activity in young healthy male volunteerscoagulationthrombus10014523NL-OMON36201Schering-Plough80